Clinical Trials Browser

Neoplasms × Carboplatin × Breast × Clear all

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03893955 2025-08-12

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

150 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03267316 2024-08-22

CANFOUR

Phase 1/2 Completed

167 enrolled

BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3 Completed

634 enrolled

Breast

Neoplasms, Triple Negative Breast Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Phase 1 Terminated

41 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01075100 2016-12-07

Ixabepilone + Carboplatin Metastatic Breast Cancer

Phase 2 Completed

103 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00002854 2015-08-26

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Phase 1 Completed

33 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Ovarian Epithelial, Anus Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Wilms Tumor, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Osteosarcoma, Stomach Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01127763 2014-04-09

RAD001 Plus Carboplatin in Breast Cancer Patients

Phase 2 Completed

25 enrolled 9 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00453635 2012-03-13

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase 2 Terminated

88 enrolled

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

9-ING-41 in Patients With Advanced Cancers

I-SPY

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

IVY

CANFOUR

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Ixabepilone + Carboplatin Metastatic Breast Cancer

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

RAD001 Plus Carboplatin in Breast Cancer Patients

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients